Cash and cash equivalents totaled $65.2 million on December 31, 2023, compared to $193.7 million on December 31, 2022. The Company estimates that its current cash and cash equivalents will fund its operations through mid-2024. This estimated cash runway does not include potential additional capital that may become available under the amendments to the strategic financing agreements or resulting from any potential financing activities that may be undertaken by the Company.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BTAI:
- BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
- Largest borrow rate increases among liquid names
- BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
- BioXcel Therapeutics downgraded to Neutral from Buy at UBS
- Bioxcel Therapeutics Unveils Corporate Progress and Strategies
